As Humira competition nears, AbbVie's Imbruvica and Mavyret pick up steam

Even as AbbVie's megablockbuster immunology med Humira inches toward its first biosim competition, the drug is still churning out record sales. Well aware of the impending competition, AbbVie has worked to diversify its offerings. Now, some other meds at the drugmaker are making a growing mark on sales charts.